October 18, 2024, Los Angels USA – Today, TenNor Therapeutics and its partners presented a series of research results on TNP-2092 (rifaquizinone) for the treatment of implantable medical device infections at the IDWeek 2024.

TenNor and its partners submitted a total of 8 abstracts on TNP-2092 to the conference and all of them were accepted. These studies covered the efficacy study of TNP-2092 administered by intra-articular injection in an animal model of artificial joint infection, the pharmacokinetics and safety study of TNP-2092 administered by intra-articular injection in rats and dogs, the absorption, metabolism and excretion study of [^C14]-TNP-2092 in healthy volunteers, the pharmacokinetics and safety bridging study of TNP-2092 in healthy Chinese volunteers, the joint tissue drug distribution and pharmacokinetics study of TNP-2092 in joint replacement patients, and the safety, efficacy and pharmacokinetics study of TNP-2092 in patients with acute bacterial skin and skin structure infections.

TenNor collaborators participating in the presentation include Rothman Orthopedic Institute, Huashan Hospital Affiliated to Fudan University, Velocity Clinical Research, Allucent Clinical Research, Pharmaron, WuXi AppTec, University of North Texas Health Science Center and Zhongnan Hospital of Wuhan University.

TNP-2092 for treating implantable medical device infections received significant attention from clinicians and researchers attending the conference.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com